Ingenuity Announces NEW Pathways Solution at Drug Discovery Technology (DDT) Conference


Drug Discovery Technology Conference, Boston – August 9, 2005 – Ingenuity announced today the upcoming release of its flagship product, IPA.

With IPA 3.0, scientists can now integrate their own biological relationships with Ingenuity networks, enabling more powerful computation and functional analysis. IPA 3.0 allows scientists to create customized pathways for particular targets, biomarkers, disease areas, and processes, leveraging Ingenuity’s broad knowledge base of biological relationships between genes and proteins, cells, tissues, and diseases. Other major features include vastly expanded search capabilities, a doubling of expert curated pathways content, and new canonical pathways. Customers can access IPA 3.0 through Ingenuity’s web based offering, or as a customized and integrated deployed solution.

“IPA 3.0 significantly extends the value of pathways and functional analysis in all areas of the R&D pipeline, addressing key bottlenecks in early discovery, biomarker identification and validation, safety assessment, and into the clinic,” stated Dr. Keith Joho, Senior Vice President of Research and Product Management.

Existing IPA customers will be upgraded at no additional cost when the product is made publicly available in September. Conference attendees can preview the new product at Booth 500 and scientists can sign up for a fully functional complimentary trial of the new release at

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View,